Drugs / MEDI3726
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02991911 | Jan 2017 → Sep 2019 | castration-resistant prostate carcinoma | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI3726 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991911 ↗ |
| Known as | ADCT-401 | “MEDI3726 (previously known as ADCT-401) is an ADC consisting of an engineered version of the anti-PSMA antibody J591 site specifically conjugated to the pyrrolobenzodiazepine...” PMID 30065100 ↗ Jul 2018 |
| Action | Deplete | “MEDI3726 specifically binds the extracellular domain of PSMA and, once internalized, releases the PBD dimer to crosslink DNA and trigger cell death.” PMID 30065100 ↗ Jul 2018 |